EPIDEMIOLOGICAL STUDY AND EVALUATION OF THE MELASQoL SCORE IN PATIENTS WITH MELASMA TREATED WITH ORAL TRANEXAMIC ACID OR TRIPLE FORMULA

• DOI: 10.22533/at.ed.15935323180710

• Palavras-chave: Melasma. MELASQoL. Triple formula. Tranexamic acid. Therapy.

• Keywords: Melasma. MELASQoL. Triple formula. Tranexamic acid. Therapy.

• Abstract:

  Melasma is an acquired hypermelanosis, which occurs mainly on the face, affecting more women and Fitzpatrick phototypes III and IV. The pathogenesis is complex and poorly understood. Genetic background and sun exposure are classic triggers. The gold standard treatment consists of agents that interfere with the synthesis and transfer of melanin, such as the triple formula that contains 4% hydroquinone, 0.05% tretinoin and 0.01% fluocinolone. Oral tranexamic acid has been studied as an alternative to treatment, as it inhibits melanogenesis and neovascularization by inhibiting plasminogen activity. This work aims to analyze the epidemiological profile and quality of life of the patients under study, with treatment with oral tranexamic acid or triple formula. We studied 24 women diagnosed with melasma, aged between 30 and 50 years, submitted to a questionnaire to assess the factors related to melasma and divided into 02 groups - group 01: oral tranexamic acid and group 02: triple formula. Photographic documentation was taken as a comparison “before and after” the intervention, and a quality of life assessment score (MELASQoL) was applied at the beginning of the study and after 60-90 days. Fourteen patients completed the 60-90 day follow-up. Ten patients dropped out of the study, nine due to absence and one due to discontinuation of treatment. Through the comparative analysis of the MELASQol of the patients in both groups at the time of inclusion and after 60-90 days of follow-up, it was possible to observe a 32.65% drop in the MELASQol of group 01 vs. 35.65% decrease in the MELASQol of group 02. Both with satisfactory results for the patients. Both oral tranexamic acid and the triple formula are drugs with a good safety profile and high effectiveness in the treatment of melasma, contributing to the improvement of the quality of life of these patients.